Combined Positive Score and Cost-Effectiveness of Perioperative Pembrolizumab for Head and Neck Cancer

In this economic evaluation, addition of perioperative pembrolizumab to standard treatment for locally advanced HNSCC may represent a cost-effective intervention for patients with a PD-L1 CPS greater than 10 if KEYNOTE-689 data are replicable in clinical practice. Perioperative pembrolizumab is not a cost-effective strategy for patients with a CPS less than 10 based on current data. Biomarker stratification may inform the value-based integration of immunotherapy among patients with HNSCC.

Corresponding Author: Pratyusha Yalamanchi, MD, MBA, Head and Neck Surgical Oncology and Microvascular Reconstruction, Department of Otolaryngology–Head and Neck Surgery, Institute for Healthcare Policy and Innovation, University of Michigan Health System, 1500 E Medical Center Dr, Ann Arbor, MI 48104 (ypratyus@med.umich.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.